Insider trading

Period: 120 months Stock: GNLX + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

122 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

122 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

122 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

122 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
122 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
122 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

122 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
27 Aug 2024
Szalay Aladar 10% owner · indirect
Sold at will
$108.86K 51,630 at 2.11
4.7%
Not planned
23 Aug 2024
Szalay Aladar 10% owner · indirect
Sold at will
$91.42K 40,000 at 2.29
3.5%
Not planned
24 Jun 2024
Yu Yong VP, Clinical Trial Operations
Sold at will
$14.52K 6,849 at 2.12
38.7%
Not planned
24 Jun 2024
Ryder Sean General Counsel
Sold at will
$11.65K 5,496 at 2.12
22.1%
Not planned
24 Jun 2024
Jewett Caroline Head of Quality
Sold at will
$10.52K 4,961 at 2.12
23.5%
Not planned
29 May 2024
Tyree James L Director
Bought
no price 6,250 shares
181%
First buy on file
29 May 2024
Smither John W Director
Bought
no price 6,250 shares
90.3%
First buy on file
29 May 2024
Thomas John Director
Bought
no price 2,500 shares
0.5%
First buy on file
29 May 2024
Mirabelli Mary Director
Bought
no price 8,000 shares
179%
First buy on file
29 May 2024
Yu Yong VP, Clinical Trial Operations
Bought
no price 2,500 shares
opened
First buy on file
29 May 2024
Zindrick Thomas President and CEO · indirect
Bought
no price 200,000 shares
opened
First buy on file
29 May 2024
Smalling Ralph Head of Regulatory
Bought
no price 1,250 shares
10.4%
First buy on file
29 May 2024
Ryder Sean General Counsel
Bought
no price 10,000 shares
×17
First buy on file
29 May 2024
Zak Lourie S. Chief Financial Officer
Bought
no price 31,250 shares
opened
First buy on file
15 May 2024
Szalay Aladar 10% owner · indirect
Sold at will
$62.62K 17,094 at 3.66
1.5%
Not planned
14 May 2024
Szalay Aladar 10% owner · indirect
Sold at will
$55.27K 15,426 at 3.58
1.3%
Not planned
13 May 2024
Szalay Aladar 10% owner · indirect
Sold at will
$12.48K 3,446 at 3.62
0.3%
Not planned
8 May 2024
Szalay Aladar 10% owner · indirect
Sold at will
$53.19K 13,919 at 3.82
1.2%
Not planned
7 May 2024
Szalay Aladar 10% owner · indirect
Sold at will
$22.11K 6,025 at 3.67
0.5%
Not planned
1 May 2024
Szalay Aladar 10% owner · indirect
Sold at will
$109.16K 33,061 at 3.30
2.7%
Not planned
30 Apr 2024
Szalay Aladar 10% owner · indirect
Sold at will
$63.98K 20,535 at 3.12
1.6%
Not planned
29 Apr 2024
Szalay Aladar 10% owner · indirect
Sold at will
$20.79K 6,403 at 3.25
0.5%
Not planned
24 Apr 2024
Szalay Aladar 10% owner · indirect
Sold at will
$28.25K 8,064 at 3.50
0.6%
Not planned
23 Apr 2024
Szalay Aladar 10% owner · indirect
Sold at will
$76.80K 22,000 at 3.49
1.7%
Not planned
22 Apr 2024
Szalay Aladar 10% owner · indirect
Sold at will
$50.60K 14,331 at 3.53
1.1%
Not planned
17 Apr 2024
Szalay Aladar 10% owner · indirect
Sold at will
$84.42K 22,737 at 3.71
1.7%
Not planned
16 Apr 2024
Szalay Aladar 10% owner · indirect
Sold at will
$171.80K 48,683 at 3.53
3.5%
Not planned
15 Dec 2023
Yu Yong VP, Clinical Trial Operations
Sold at will 2×
$428.18K 32,535 at 13.16
100%
Sold half or more
13 Dec 2023
Thomas John Director
Sold at will 2×
$120.39K 9,000 at 13.38
1.9%
Not planned
13 Dec 2023
Tyree James L Director
Sold at will 2×
$118.97K 9,000 at 13.22
72.2%
Sold half or more
7 Dec 2023
Yu Yong VP, Clinical Trial Operations
Sold at will
$436.00K 36,800 at 11.85
53.1%
Sold half or more
21 Nov 2023
Yu Yong VP, Clinical Trial Operations
Sold at will
$191.56K 18,665 at 10.26
21.2%
Not planned
20 Nov 2023
Yu Yong VP, Clinical Trial Operations
Sold at will
$164.26K 14,594 at 11.26
14.2%
Not planned
17 Nov 2023
Yu Yong VP, Clinical Trial Operations
Sold at will
$46.17K 3,541 at 13.04
3.3%
Not planned
25 Oct 2023
Szalay Aladar 10% owner · indirect
Sold at will
$110.64K 5,704 at 19.40
0.4%
Not planned
24 Oct 2023
Yu Yong VP, Clinical Trial Operations
Sold at will
$99.35K 5,200 at 19.11
4.7%
Not planned
23 Oct 2023
Szalay Aladar 10% owner · indirect
Sold at will
$998.37K 49,987 at 19.97
3.5%
Not planned
16 Oct 2023
Thomas John Director
Sold at will 2×
$69.04K 3,333 at 20.71
0.7%
Not planned
10 Oct 2023
Yu Yong VP, Clinical Trial Operations
Sold at will 2×
$114.46K 5,200 at 22.01
4.7%
Not planned
5 Oct 2023
Szalay Aladar 10% owner · indirect
Sold at will 2×
$355.23K 14,251 at 24.93
1.0%
Not planned
3 Oct 2023
Szalay Aladar 10% owner · indirect
Sold at will
$1.93M 75,690 at 25.49
5.0%
Not planned
28 Sep 2023
Szalay Aladar 10% owner · indirect
Sold at will
$55.21K 2,289 at 24.12
0.2%
Not planned
27 Sep 2023
Szalay Aladar 10% owner · indirect
Sold at will
$275.46K 11,257 at 24.47
0.7%
Not planned
26 Sep 2023
Szalay Aladar 10% owner · indirect
Sold at will 3×
$709.18K 29,805 at 23.79
1.9%
Not planned
26 Sep 2023
Yu Yong VP, Clinical Trial Operations
Sold at will 3×
$122.53K 5,200 at 23.56
4.7%
Not planned
25 Sep 2023
Szalay Aladar 10% owner · indirect
Sold at will 4×
$321.00K 12,458 at 25.77
0.8%
Not planned
22 Sep 2023
Szalay Aladar 10% owner · indirect
Sold at will 2×
$247.12K 9,042 at 27.33
0.6%
Not planned
21 Sep 2023
Szalay Aladar 10% owner · indirect
Sold at will 2×
$214.88K 7,549 at 28.46
0.5%
Not planned
20 Sep 2023
Ryder Sean General Counsel
Sold at will
$300.00K 10,000 at 30.00
94.6%
Sold half or more
20 Sep 2023
Yu Yong VP, Clinical Trial Operations
Sold at will
$167.79K 6,000 at 27.96
5.4%
Not planned
Showing 51–100 of 122. ← Newer Page 2 of 3 Older →